Fig 1. TNBC cell lines have diverse sensitivity to Plk1 inhibition and chemotherapy.

TNBC cell lines: SUM149, SUM159, SUM229, SUM1315 and DU4475 cells, and the non-tumorigenic human breast epithelial cell line MCF10A. TNBC cell lines were treated for 72 hours in triplicates. Three replicate data were performed for each concentration and the best dose–response model (r conformity closest to 1) was selected and graphed. After a 72 hours exposure to drug, cell number was determined by harvesting and counting nuclei with a Beckman Coulter Z1 Particle Counter. IC₅₀, IC₂₅, and r conformity were determined using CompuSyn software. (A) Sensitivity to GSK461364, Plk1 inhibitor, in TNBC cell lines; IC₅₀, IC₂₅, and r conformity were reported for GSK461364. (B) TNBC cell lines sensitivity with respective IC₅₀ and r conformity to docetaxel. (C) TNBC cell lines sensitivity with respective IC₅₀ and r conformity to cisplatin.